Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Mobile infliximab dosing calculator for therapy optimization in IBD

February's issue of the Inflammatory Bowel Diseases investigates a mobile infliximab dosing calculator for therapy optimization in IBD.

News image

Inadequate infliximab drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD).

Dr Travis Piester and colleagues determined the feasibility and pilot effectiveness of a novel, web-based, mobile infliximab dosing calculator for therapy optimization.

The researchers developed an mobile infliximab dosing calculator leveraging the known clinical variables of C-reative protein (CRP), albumin, patient’s weight, disease activity indices, calprotectin, drug trough levels, and antibodies to infliximab that significantly affect pharmacokinetics and/or outcomes.

A prospective observational cohort study in pediatric and young adult IBD patients receiving maintenance infliximab was performed.

System-wide practice adoption of mobile infliximab dosing calculator was achieved through a quality improvement (QI) initiative within a hospital-based infusion unit.

The team noted that 49 patients were followed over 9 months.

Infliximab trough goal of >5 μg/mL was achieved with 81% probability throughout the QI initiative
Inflammatory Bowel Diseases

Mobile infliximab dosing calculator recommendations for dose optimization were followed by the treating physicians in 89% of infusions.

The researchers noted that 13% of mobile infliximab dosing calculator recommendations were to escalate infliximab dosing.

The team noted that 54% of escalation recommendations were declined, and these patients were more likely to already be receiving infliximab dose intensification compared with those in whom escalation recommendations were followed.

From mobile infliximab dosing calculator initiation to end of follow-up, mean albumin levels remained unchanged at 3.8 g/dL.

The research team observed that the median CRP remained unchanged at 2 g/L.

Median calprotectin levels showed a downward trend from 30 to 27 μg/g.

The team found that the percentage of patients undergoing therapeutic drug monitoring in clinical care increased from 34% to 86% with the QI initiative.

The target median infliximab trough goal of >5 μg/mL was achieved with 81% probability throughout the QI initiative, an increase of 12% compared with pre-QI values.

Dr Piester's team concludes, "The use of a novel mobile infliximab dosing calculator is feasible and potentially effective, facilitating both standardization and individualization of therapy in clinical care."

"Mobile infliximab dosing calculator appears to be a practical infliximab dosing tool for point-of-care use, leveraging individual pharmacokinetic considerations."

Inflamm Bowel Dis 2018: 24(2): 227–234
29 January 2018

Go to top of page Email this page Email this page to a colleague

 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us